Tizanidine Tablet
Product Images NDC 67296-2316

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 67296-2316). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Redpharm Drug, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Container1 (Container1)

Label for Tizanidine Tablets, USP 2 mg oral tablets, supplied in a package of 150 tablets. The label includes storage instructions, a warning that tablets are not interchangeable with Tizanidine Capsules, manufacturing information for Northstar Rx LLC and Dr. Reddy's Laboratories, and a barcode.*

FDA Label Image

Container2 (Container2)

Label for Tizanidine Tablets USP 4 mg, showing dosage strength and quantity of 150 tablets. The label includes a warning that these tablets are not interchangeable with Tizanidine Capsules. It specifies the active ingredient amount per tablet and storage instructions, with manufacturer details listed as Dr. Reddy's Laboratories Limited, India, and labeler Northstar Rx LLC, Memphis, TN.*

FDA Label Image

Fig1 (Fig1)

A line graph showing plasma Tizanidine concentration (ng/mL) over time (hours) after dosing. It compares four scenarios: 2 x 4 mg Tizanidine tablets with food, without food, and 2 x 4 mg Tizanidine capsules with and without food. The graph tracks concentration changes from 0 to 24 hours post-dosing.*

FDA Label Image

Fig2 (Fig2)

A line graph showing improvement in Ashworth Score over time (hours post-dose) comparing 16 mg tizanidine, 8 mg tizanidine, and placebo. The y-axis represents improvement in Ashworth Score from 0 to -5, and the x-axis shows time from 0 to 6 hours after dosing. Data points include error bars indicating variability for each treatment group over time.*

FDA Label Image

Fig3 (Fig3)

A line chart comparing improvement in Ashworth Score for Tizanidine (mean dose 28.8 mg) versus placebo at three time points: End of Titration (Week 3), End of Maintenance (Week 7), and Endpoint (Last Observation Carried Forward). The chart shows mean values with error bars for both groups across study periods.*

FDA Label Image

Structure (Structure)

Chemical structure of Tizanidine hydrochloride, showing its molecular framework with a fused benzothiazole and imidazoline ring system.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.